TUESDAY, Feb. 13, 2024 (HealthDay News) — Despite weight gain (WR), remission rates for type 2 diabetes mellitus (T2DM) are commonly maintained after Roux-en-Y gastric bypass (RYGB). This was revealed in a study published online in February. .13 Journal of the American College of Surgeons.
Omar M. Ghanem, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a retrospective review of patients with a BMI of 35 kg/m or higher who underwent successful primary RYGB or sleeve gastrectomy (SG).2 and preoperative diagnosis of T2DM. Continuous diabetes remission rates (CDRs) were stratified into WR quartiles and compared after selecting the optimal procedure for glycemic control.
Data were analyzed for 224 patients with RYGB and 46 patients with SG. The overall CDR rate was higher in his RYGB group than in the SG group (75 vs. 34.8 percent). The probability of T2DM recurrence was 5.5 times higher after SG than after RYGB. WR quartile (<25、25 ～ 44.9、45 ～ 74.9、および >75 percent), the CDR rates were 85.5, 81.7, 63.2, and 60 percent, respectively. Baseline insulin use, elevated preoperative hemoglobin A1c, and prolonged preoperative period of T2DM were associated with T2DM recurrence. WR was not associated with his T2DM recurrence.
“Even though WR is not an independent factor associated with T2DM recurrence, its importance cannot be ignored,” the authors wrote. “Some patients with complete WR after RYGB maintain significant CDR, further supporting the potential role of the proximal small intestine in metabolic control that is less dependent on weight loss through gastric restriction. ”
Several authors disclosed relationships with the pharmaceutical and medical device industries.
